AnaptysBio stock
ANABNASDAQAnaptysBio, Inc., HealthcareISIN US0327241065
60Score 60 out of 100, Neutral
Price and trend
48 / 100
Price history
+117% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.6% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 32% below its 52-week high. Largest decline in 10 years: 92% (March 2018 to November 2019).
Chart figures for advanced users
- SMA 50$50.01
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$51.13
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.06
- The lowest closing price of the last twelve months.
- Resistance$69.81
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- AnaptysBio, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.43B, is number 154 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $234.6M (up 157% year on year) and a loss of $13.23M.
- For fiscal 2026, analysts expect on average revenue of $138.05M (down 41.2%) and adjusted earnings per share of $5.07.
Show more
- MEQIRI Score 60 out of 100 (Neutral): rank 263 of 702 in Healthcare, median 53.
- Our model puts fair value at $60.30, with the price 21% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 96.3% over the last 12 months, Biotechnology median −103.7%.Profitability 99
- More cash than debtCash $311.64M, financial debt $290.64M (debt as of 31 Dec 2025).
Weaknesses
- High debtDebt 7.81 times equity (debt as of 31 Dec 2025), Biotechnology median 0.09.Stability 28
- Interest barely coveredOperating profit covers interest only 0.8 times.Stability 28
- Volatile share priceVolatility 61% a year over the last 12 months.Stability 28
Its standout strengths are profitability and valuation, while fundamentals and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 64 to 60.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price up very strongly over the past year
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $40.20 and expensive above $120.59 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $10.40 (cash-flow model) and $110.19 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $59.55, at 8.9% it would be $61.33.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13% on the twelve months before. Revenue has grown strongly since 2013, at around 37% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 99%, operating 20%, net −6%. Last 12 months: net 96%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 12 Nov 2026EPS reported $0.11 (expected −$1.84)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $5.070.0%
- Revenue
- $138.05M+19.4%
- Earnings per share
- $6.750.0%
- Revenue
- $243.29M+24.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $249,372 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Renton HollingsSale
1 Oct 2026, Board
- Shares
- 5,000
- Price
- $49.87
- Value
- $249,372
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at AnaptysBio
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 60
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AbsciABSI $1.57B38
- Intellia TherapeuticsNTLA $1.48B33
- NovavaxNVAX $1.45B42
- Nuvation BioNUVB $1.43B29
- Alto NeuroscienceANRO $1.42B41
- Ascentage Pharma Group InternationalAAPG $1.4B37
- Ocular TherapeutixOCUL $1.38B34
- LB PharmaceuticalsLBRX $1.37B49
ETFs that hold AnaptysBio
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.10% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.25B |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.09% | 0.40% | €813.42M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.22B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.5B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.